Brought to you by 
Zealand Pharma licenses Aventis rights to diabetes compound
07 Sep 2018
Executive Summary
Biopharmaceutical company Zealand Pharma AS (therapeutics for diabetes, cardiac arrhythmia, and heart failure) licensed Aventis worldwide rights to its lead compound ZP10, a glucagon-like peptide-1 (GLP-1) receptor agonist in Phase I/IIa clinical trials to treat Type II diabetes.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zealand Pharma licenses Aventis rights to diabetes compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice